When inappropriate subjects are enrolled into a clinical trial, the success of the study can be at risk. Sponsors seek to protect the integrity of their study by identifying subjects who violate the protocol, and preventing them from being inappropriately randomized to treatment. Dr. Edward Bartolic, Senior Scientific Director at Cogstate, gives an overview and case example of our Subject Eligibility Review and Diagnostic Adjudication solution, an independent check of key screening data by our expert clinicians to ensure that a subject fits with the key clinical eligibility criteria of a protocol.